From GlobeNewswire: 2025-03-13 07:30:00

Indaptus Therapeutics, Inc. achieves a key clinical milestone with over 20 patients enrolled in Phase 1 trial of Decoy20. Pharmacodynamic immune activation biomarker and pharmacokinetics profiles meet expectations. Some patients show signs of Stable Disease, with expansion into combination therapy with BeiGene’s PD-1 inhibitor planned for 2025. Financial results show progress in research and development, with cash and cash equivalents of $5.8 million as of December 31, 2024. Loss per share for the year ended December 31, 2024, was $1.61. The Company plans to dose the first patients in a combination study with BeiGene’s Tislelizumab and provide further clinical updates in 2025.

Indaptus Therapeutics’ patented Decoy platform shows promise in activating immune cells and pathways against tumors and viruses. Pre-clinical studies demonstrate the platform’s effectiveness in eradicating various cancers and infectious diseases. The Company continues to assess financing options to support its corporate strategy. Consolidated financial statements for the year ended December 31, 2024, show a net loss of $15,022,027 and cash flows used in operating activities of $12,323,188. Cash and cash equivalents at the end of the year were $5,786,753.

The Company’s focus on advancing Decoy20 in clinical trials and exploring potential combinations with other therapies highlights its commitment to innovative treatments for difficult-to-treat cancers. The progress made in research and development, along with financial results, positions Indaptus Therapeutics for continued growth and success in the biopharmaceutical industry.



Read more at GlobeNewswire:: Indaptus Therapeutics Reports Fourth Quarter and Year-End